Impact of body composition for patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab therapy.

Haruki Uojima,Makoto Chuma,Hisashi Hidaka,Takashi Tsuda,Satoshi Kobayashi,Nobuhiro Hattori,Katsuaki Ogushi,Yoshitaka Arase,Akira Take,Yoshihiko Sakaguchi, Ando Tomoko, Shuhei Nishigori, Tsunamasa Wanatanbe,Kazushi Numata,Manabu Morimoto,Tatehiro Kagawa,Makoto Kako,Chika Kusano

European journal of gastroenterology & hepatology（2023）

引用 0|浏览17

暂无评分

摘要

Low visceral fat index and subcutaneous fat index scores were independent predictors of poor prognosis in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

查看译文

关键词

hepatocellular carcinoma,atezolizumab,bevacizumab,body composition

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要